ORIGINAL RESEARCH Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study) Blanca Herna ´ndez-Cruz . Jose ´ Rosas . Ce ´sar Dı ´az-Torne ´ . Joaquı ´n Belzunegui . Rosario Garcı ´a-Vicun ˜a . Jose ´ Inciarte-Mundo . Ana Pons . Ana M. Milla ´n . Sicylle Jeria-Navarro . Jesu ´ s A. Valero . Noelia Garcı ´a-Castan ˜eda . Cristina Valero . Irene Llorente . Alberto Calvo . Silvia Dı ´az-Cerezo . Mercedes Nu ´n ˜ez Received: November 10, 2021 / Accepted: December 22, 2021 Ó The Author(s) 2022 ABSTRACT Introduction: Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved to treat rheumatoid arthritis (RA). This study aimed to investigate patients’ characteristics, prescription patterns, effectiveness, and treatment persis- tence in patients receiving baricitinib in real- world practice in Spain. Methods: This retrospective longitudinal cohort study conducted in five rheumatology units included adults with RA initiating barici- tinib (Sep-2017–May-19) with at least a 6-month-follow-up. Demographic/clinical characteristics, prescription patterns, and changes in disease activity and pain level were collected until treatment discontinuation/end of follow-up. Treatment persistence was esti- mated by Kaplan–Meier methods. Results: Data from 182 patients were included (mean (SD)): 83.5% women, 62.2 (12.3) years, Supplementary Information The online version contains supplementary material available at https:// doi.org/10.1007/s40744-021-00423-8. B. Herna ´ndez-Cruz (&) Rheumatology Department, University Hospital Virgen Macarena, Calle Dr. Fedriani, 3, 41009 Seville, Spain e-mail: blancahcruz@gmail.com; blancae.hernandez.sspa@juntadeandalucia.es J. Rosas Á A. Pons Rheumatology Department, Marina Baixa Hospital, Av. Alcalde En Jaume Botella Mayor, 7, Villajoyosa, 03570 Alicante, Spain C. Dı ´az-Torne ´ Á A. M. Milla ´n Á S. Jeria-Navarro Arthritis Unit, Rheumatology and Autoimmune Diseases Department, Santa Creu i Sant Pau Hospital, Carrer de Sant Quintı ´, 89, 08041 Barcelona, Spain J. Belzunegui Á J. A. Valero Rheumatology Department, Donostia University Hospital, Begiristain Doktorea Pasealekua, 20014 Guipu ´ zcoa, Spain R. Garcı ´a-Vicun ˜a Á N. Garcı ´a-Castan ˜eda Á C. Valero Á I. Llorente Á A. Calvo Rheumatology Department, University Hospital La Princesa, IIS-IP, Calle de Diego de Leo ´ n, 62, 28006 Madrid, Spain J. Inciarte-Mundo Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, C. de Villarroel, 170, 08036 Barcelona, Spain S. Dı ´az-Cerezo Á M. Nu ´n ˜ez Medical Department, Lilly Spain, Av de la Industria 30, Alcobendas, 28108 Madrid, Spain Rheumatol Ther https://doi.org/10.1007/s40744-021-00423-8